Wang Ziqiong, Chen Bo, Chen Jiyang, Wu Zhixuan, Gu Hongyi, Wang Ying, Dai Xuanxuan
Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
The First Clinical College, Wenzhou Medical University, Wenzhou, China.
Front Oncol. 2022 Feb 14;12:798016. doi: 10.3389/fonc.2022.798016. eCollection 2022.
The impact of primary site surgery on survival remains controversial in female patients with stage IV breast cancer. The purpose of this study was to investigate the role of primary tumor surgery in patients with stage IV breast cancer and concurrently develop a nomogram to identify which patients will benefit from surgery.
We retrospectively searched the SEER database for female patients newly diagnosed with stage IV breast infiltrating duct carcinoma (BIDC) between 2010 and 2015 and then divided them into surgery and non-surgery groups. The propensity score matching (PSM) method was implemented to eliminate the bias, and Kaplan-Meier survival analysis was generated to compare the overall survival (OS) and cancer-specific survival (CSS) between the two groups. After PSM, Cox regression analyses were performed to determine the independent protective value of primary tumor surgery, while logistic regression analyses were utilized to uncover significant predictors of surgical benefit and establish a screening nomogram for female patients with stage IV BIDC. Nomogram performance was evaluated by calibration curves, receiver operating characteristic (ROC) curves, and decision curve analysis (DCA).
5,475 patients with stage IV BIDC were included in this study, and 2,375 patients (43.38%) received primary tumor surgery. After PSM, the median CSS was 53 months (95% CI: 46.84-59.16) in the surgery group compared with only 33 months (95% CI: 30.05-35.95) in the non-surgery group. We further found that primary tumor surgery was an independent protective factor for patients with stage IV BIDC. The independent factors affecting the benefit of locoregional surgery in patients with stage IV BIDC included histological grade, T stage, molecular subtype, lung metastasis, liver metastasis, brain metastasis, and marital status. The AUC of the nomogram was 0.785 in the training set and 0.761 in the testing set. The calibration curves and DCA confirmed that the nomogram could precisely predict the possibility of benefit from primary tumor resection.
Our study suggested that primary tumor surgery improved the prognosis of female patients with stage IV BIDC and developed a nomogram to quantify the probability of surgical benefit to help identify surgical candidates clinically.
对于IV期乳腺癌女性患者,原发部位手术对生存的影响仍存在争议。本研究的目的是探讨原发肿瘤手术在IV期乳腺癌患者中的作用,并同时开发一种列线图以识别哪些患者将从手术中获益。
我们回顾性检索了监测、流行病学和最终结果(SEER)数据库,以查找2010年至2015年间新诊断为IV期乳腺浸润性导管癌(BIDC)的女性患者,然后将她们分为手术组和非手术组。采用倾向评分匹配(PSM)方法消除偏差,并进行Kaplan-Meier生存分析以比较两组之间的总生存期(OS)和癌症特异性生存期(CSS)。PSM后,进行Cox回归分析以确定原发肿瘤手术的独立保护价值,同时利用逻辑回归分析揭示手术获益的显著预测因素,并为IV期BIDC女性患者建立筛查列线图。通过校准曲线、受试者工作特征(ROC)曲线和决策曲线分析(DCA)评估列线图性能。
本研究纳入了5475例IV期BIDC患者,其中2375例(43.38%)接受了原发肿瘤手术。PSM后,手术组的中位CSS为53个月(95%CI:46.84 - 59.16),而非手术组仅为33个月(95%CI:30.05 - 35.95)。我们进一步发现,原发肿瘤手术是IV期BIDC患者的独立保护因素。影响IV期BIDC患者局部区域手术获益的独立因素包括组织学分级、T分期、分子亚型、肺转移、肝转移、脑转移和婚姻状况。列线图在训练集中的AUC为0.785,在测试集中为0.761。校准曲线和DCA证实列线图可以准确预测从原发肿瘤切除中获益的可能性。
我们的研究表明,原发肿瘤手术改善了IV期BIDC女性患者的预后,并开发了一种列线图来量化手术获益的概率,以帮助在临床上识别手术候选者。